Study of Apatinib as 3rd/4th Line Treatment in Patients With Advanced Non-Squamous Non-small Cell Lung Cancer Harboring Wild-type Epidermal Growth Factor Receptor (EGFR)

Name: Study of Apatinib as 3rd/4th Line Treatment in Patients With Advanced Non-Squamous Non-small Cell Lung Cancer Harboring Wild-type Epidermal Growth Factor Receptor (EGFR)
Published: 2015
License: Public Domain

Jiangsu HengRui Medicine Co., Ltd. · 2015

ClinicalTrials.gov · Datasets · License: Public Domain · 2015

Open Source ↗

carcinoma

carcinoma, non-small-cell lung, non-squamous non-small cell lung cancer, wild-type egfr, 3rd/4th line treatment, apatinib, interventional, phase3

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Study of Apatinib as 3rd/4th Line Treatment in Patients With Advanced Non-Squamous Non-small Cell Lung Cancer Harboring Wild-type Epidermal Growth Factor Receptor (EGFR)

Related documents